Analysis of risk factors for depression in Alzheimer’s disease patients

References

• Chan KY, Wang W, Wu JJ, et al. Epidemiology of Alzheimer’s disease and other forms of dementia in China, 1990–2010: a systematic review and analysis. Lancet (London, England.) 2013;381(9882):2016–2023.
   PubMed Web of Science ®Google Scholar
• Savva GM, Zaccai J, Matthews FE, et al. Prevalence, correlates and course of behavioural and psychological symptoms of dementia in the population. Br J Psychiatry. 2009;194(3):212–219.
   PubMed Web of Science ®Google Scholar
• Mayor S. Signs of depression and apathy precede memory problems in Alzheimer’s disease, study shows. BMJ (Clinical research ed). 2015;350:h190.
   PubMedGoogle Scholar
• Masters MC, Morris JC, Roe CM. Noncognitive symptoms of early Alzheimer disease: a longitudinal analysis. Neurology. 2015;84(6):617–622.
   PubMed Web of Science ®Google Scholar
• Wuwongse S, Chang RC, Law AC. The putative neurodegenerative links between depression and Alzheimer’s disease. Prog Neurobiol. 2010;91(4):362–375.
   PubMed Web of Science ®Google Scholar
• Kloppel S, Kotschi M, Peter J, et al. Separating symptomatic Alzheimer’s disease from depression based on structural MRI. JAD. 2018;63(1):353–363.
   Web of Science ®Google Scholar
• Banerjee S, Hellier J, Dewey M, et al. Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. Lancet (London, England.) 2011;378(9789):403–411.
   PubMed Web of Science ®Google Scholar
• Sepehry AA, Lee PE, Hsiung GY, et al. Effect of selective serotonin reuptake inhibitors in Alzheimer’s disease with comorbid depression: a meta-analysis of depression and cognitive outcomes. Drugs Aging. 2012;29(10):793–806.
   PubMed Web of Science ®Google Scholar
• Lenze EJ, Skidmore ER, Begley AE, et al. Memantine for late-life depression and apathy after a disabling medical event: a 12-week, double-blind placebo-controlled pilot study. Int J Geriatr Psychiatry. 2012;27(9):974–980.
   PubMed Web of Science ®Google Scholar
• Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6(8):734–746.
   PubMed Web of Science ®Google Scholar
• Johnson LA, Cushing B, Rohlfing G, et al. The Hachinski ischemic scale and cognition: the influence of ethnicity. Age Ageing. 2014;43(3):364–369.
   PubMed Web of Science ®Google Scholar
• McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology. 2017;89(1):88–100.
   PubMed Web of Science ®Google Scholar
• Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain: J Neurol. 2011;134(9):2456–2477.
   Web of Science ®Google Scholar
• Ravona-Springer R, Heymann A, Schmeidler J, et al. Hemoglobin A1c variability predicts symptoms of depression in elderly individuals with type 2 diabetes. Dia Care. 2017;40(9):1187–1193.
   PubMed Web of Science ®Google Scholar
• Honig LS, Vellas B, Woodward M, et al. Trial of solanezumab for mild dementia due to Alzheimer’s disease. N Engl J Med. 2018;378(4):321–330.
   PubMed Web of Science ®Google Scholar
• Chen J, Shu H, Wang Z, et al. Convergent and divergent intranetwork and internetwork connectivity patterns in patients with remitted late-life depression and amnestic mild cognitive impairment. Cortex: a journal devoted to the study of the nervous system and behavior. 2016;83:194–211.
   PubMed Web of Science ®Google Scholar
• Starkstein SE, Jorge R, Mizrahi R, et al. The construct of minor and major depression in Alzheimer’s disease. AJP. 2005;162(11):2086–2093.
   Web of Science ®Google Scholar
• Leal SL, Noche JA, Murray EA, et al. Disruption of amygdala-entorhinal-hippocampal network in late-life depression. Hippocampus. 2017;27(4):464–476.
   PubMed Web of Science ®Google Scholar
• Loonen AJ, Ivanova SA. Circuits regulating pleasure and happiness in major depression. Med Hypotheses. 2016;87:14–21.
   PubMed Web of Science ®Google Scholar
• Ulrich-Lai YM, Herman JP. Neural regulation of endocrine and autonomic stress responses. Nat Rev Neurosci. 2009;10(6):397–409.
   PubMed Web of Science ®Google Scholar
• Roy T, Lloyd CE. Epidemiology of depression and diabetes: a systematic review. J Affective Disord. 2012;142 (Suppl):S8–S21.
   PubMed Web of Science ®Google Scholar
• Moulton CD, Pickup JC, Ismail K. The link between depression and diabetes: the search for shared mechanisms. Lancet Diabetes Endocrinol. 2015;3(6):461–471.
   PubMed Web of Science ®Google Scholar
• Stetler C, Miller GE. Depression and hypothalamic-pituitary-adrenal activation: a quantitative summary of four decades of research. Psychosomatic Med. 2011;73(2):114–126.
   PubMed Web of Science ®Google Scholar
• Ridler C. Alzheimer disease: misfolded diabetes-mellitus peptide seeds amyloid-beta aggregation. Nat Rev Neurol. 2017;13(3):128–128.
   PubMedGoogle Scholar
• Leboucher A, Laurent C, Fernandez-Gomez FJ, et al. Detrimental effects of diet-induced obesity on tau pathology are independent of insulin resistance in tau transgenic mice. Diabetes. 2013;62(5):1681–1688.
   PubMed Web of Science ®Google Scholar
• Willette AA, Johnson SC, Birdsill AC, et al. Insulin resistance predicts brain amyloid deposition in late middle-aged adults. Alzheimer’s Dementia: J Alzheimer’s Assoc. 2015;11(5):504–510.e1.
   PubMed Web of Science ®Google Scholar
• Roberts RO, Knopman DS, Przybelski SA, et al. Association of type 2 diabetes with brain atrophy and cognitive impairment. Neurology. 2014;82(13):1132–1141.
   PubMed Web of Science ®Google Scholar
• Gonzalez JS, Peyrot M, McCarl LA, et al. Depression and diabetes treatment nonadherence: a meta-analysis. Diabetes Care. 2008;31(12):2398–2403.
   PubMed Web of Science ®Google Scholar
• Khambaty T, Stewart JC, Muldoon MF, et al. Depressive symptom clusters as predictors of 6-year increases in insulin resistance: data from the Pittsburgh Healthy Heart Project. Psychosomatic Med. 2014;76(5):363–369.
   PubMed Web of Science ®Google Scholar
• Shi Q, Liu S, Fonseca VA, et al. Effect of metformin on neurodegenerative disease among elderly adult US veterans with type 2 diabetes mellitus. BMJ Open. 2019;9(7):e024954.
   PubMed Web of Science ®Google Scholar
• Kickstein E, Krauss S, Thornhill P, et al. Biguanide metformin acts on tau phosphorylation via mTOR/protein phosphatase 2A (PP2A) signaling. PNAS. 2010;107(50):21830–21835.
   PubMed Web of Science ®Google Scholar
• Gupta A, Bisht B, Dey CS. Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer’s-like changes. Neuropharmacology. 2011;60(6):910–920.
   PubMed Web of Science ®Google Scholar
• Hsu CC, Wahlqvist ML, Lee MS, et al. Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin. JAD. 2011;24(3):485–493.
   Web of Science ®Google Scholar
• Ouwens DM, van Duinkerken E, Schoonenboom SN, et al. Cerebrospinal fluid levels of Alzheimer’s disease biomarkers in middle-aged patients with type 1 diabetes. Diabetologia. 2014;57(10):2208–2214.
   PubMed Web of Science ®Google Scholar
• Bomfim TR, Forny-Germano L, Sathler LB, et al. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer’s disease- associated Abeta oligomers. J Clin Invest. 2012;122(4):1339–1353.
   PubMed Web of Science ®Google Scholar
• McIntosh EC, Nation DA. Importance of Treatment status in links between type 2 diabetes and Alzheimer’s disease. Dia Care. 2019;42(5):972–979.
   PubMed Web of Science ®Google Scholar
• Katsel P, Roussos P, Beeri MS, et al. Parahippocampal gyrus expression of endothelial and insulin receptor signaling pathway genes is modulated by Alzheimer’s disease and normalized by treatment with anti-diabetic agents. PloS ONE. 2018;13(11):e0206547.
   PubMed Web of Science ®Google Scholar
• Sanahuja J, Alonso N, Diez J, et al. Increased burden of cerebral small vessel disease in patients with type 2 diabetes and retinopathy. Dia Care. 2016;39(9):1614–1620.
   PubMed Web of Science ®Google Scholar
• Craft S, Watson GS. Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol. 2004;3(3):169–178.
   PubMed Web of Science ®Google Scholar
• Craft S, Claxton A, Baker LD, et al. Effects of regular and long-acting insulin on cognition and Alzheimer’s disease biomarkers: a pilot clinical trial. JAD. 2017;57(4):1325–1334.
   Web of Science ®Google Scholar
• Esmaeili MH, Bahari B, Salari AAA. sensitive potassium-channel inhibitor glibenclamide attenuates HPA axis hyperactivity, depression- and anxiety-related symptoms in a rat model of Alzheimer’s disease. Brain Res Bull. 2018;137:265–276.
   PubMed Web of Science ®Google Scholar